RogCon Biosciences Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
7
- Latest Deal Type
-
Out of Business
RogCon Biosciences General Information
Description
Developer of a novel therapeutics technology designed to treat children suffering from SCN2A mutations. The company's therapeutics treat genetic epilepsy and other genetic diseases, enabling clinicians to take deliberate action on mutation-related diseases.
Contact Information
Website
www.rogcon.comCorporate Office
- 5251 Lagorce Drive
- Miami Beach, FL 33140
- United States
Corporate Office
- 5251 Lagorce Drive
- Miami Beach, FL 33140
- United States
RogCon Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 27-Dec-2023 | Completed | Out of Business | |||
| 1. Seed Round | 03-Apr-2017 | Completed | Generating Revenue |
RogCon Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
RogCon Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
RogCon Biosciences Patents
RogCon Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019325255-A1 | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies | Active | 20-Aug-2018 | ||
| AU-2019325255-B2 | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies | Active | 20-Aug-2018 | ||
| CA-3110211-A1 | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies | Pending | 20-Aug-2018 | ||
| EP-3840733-A1 | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies | Pending | 20-Aug-2018 | ||
| EP-3840733-A4 | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies | Pending | 20-Aug-2018 | C12N15/1138 |
RogCon Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
RogCon Biosciences FAQs
-
When was RogCon Biosciences founded?
RogCon Biosciences was founded in 2015.
-
Where is RogCon Biosciences headquartered?
RogCon Biosciences is headquartered in Miami Beach, FL.
-
What is the size of RogCon Biosciences?
RogCon Biosciences has 7 total employees.
-
What industry is RogCon Biosciences in?
RogCon Biosciences’s primary industry is Drug Discovery.
-
Is RogCon Biosciences a private or public company?
RogCon Biosciences is a Private company.
-
What is RogCon Biosciences’s current revenue?
The current revenue for RogCon Biosciences is .
-
How much funding has RogCon Biosciences raised over time?
RogCon Biosciences has raised $1.14M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
